PURPOSE: To assess the effect of treatment waiting time on clinical outcome for patients with cervix cancers treated with radical radiotherapy. METHODS AND MATERIALS: A retrospective analysis was conducted on all cervix cancer patients treated with radical radiotherapy between 1990 and 2001 at the Ottawa Regional Cancer Centre. Analyses were performed according to the three following separate definitions of waiting times: interval from start of radiotherapy to (1) date of initial biopsy, (2) date of examination under anesthesia, and (3) date of radiation oncology consultation. Associations between waiting times and patient characteristics and disease control were investigated using t-tests, analyses of variance, and Cox regression analyses. RESULTS: A total of 195 patients were studied. The vast majority of patients were treated within 5, 6, and 8 weeks of their consultation (91%), examination under anesthesia (88%), and biopsy (81%), respectively. On average, delays between initial biopsy and treatment start were greater for older patients (p = 0.025) (5.8 weeks for <40 years old vs. 6.6 weeks for >70 years old) and those with smaller tumors (p < 0.001) (5.0 weeks for >4 cm vs. 6.3 weeks for < or =4 cm). Univariate analysis revealed no adverse effect of treatment delay on tumor control. Multivariate analysis, with the inclusion of multiple prognostic tumor and treatment parameters, revealed an adverse effect of treatment delay on survival outcomes. CONCLUSIONS: Longer radiotherapy waiting times were found to be associated with diminished survival outcomes for patients treated radically for cervix cancer. The significance of this observed association requires further investigation.
PURPOSE: To assess the effect of treatment waiting time on clinical outcome for patients with cervix cancers treated with radical radiotherapy. METHODS AND MATERIALS: A retrospective analysis was conducted on all cervix cancerpatients treated with radical radiotherapy between 1990 and 2001 at the Ottawa Regional Cancer Centre. Analyses were performed according to the three following separate definitions of waiting times: interval from start of radiotherapy to (1) date of initial biopsy, (2) date of examination under anesthesia, and (3) date of radiation oncology consultation. Associations between waiting times and patient characteristics and disease control were investigated using t-tests, analyses of variance, and Cox regression analyses. RESULTS: A total of 195 patients were studied. The vast majority of patients were treated within 5, 6, and 8 weeks of their consultation (91%), examination under anesthesia (88%), and biopsy (81%), respectively. On average, delays between initial biopsy and treatment start were greater for older patients (p = 0.025) (5.8 weeks for <40 years old vs. 6.6 weeks for >70 years old) and those with smaller tumors (p < 0.001) (5.0 weeks for >4 cm vs. 6.3 weeks for < or =4 cm). Univariate analysis revealed no adverse effect of treatment delay on tumor control. Multivariate analysis, with the inclusion of multiple prognostic tumor and treatment parameters, revealed an adverse effect of treatment delay on survival outcomes. CONCLUSIONS: Longer radiotherapy waiting times were found to be associated with diminished survival outcomes for patients treated radically for cervix cancer. The significance of this observed association requires further investigation.
Authors: Margaret E Kruk; Anna D Gage; Catherine Arsenault; Keely Jordan; Hannah H Leslie; Sanam Roder-DeWan; Olusoji Adeyi; Pierre Barker; Bernadette Daelmans; Svetlana V Doubova; Mike English; Ezequiel García-Elorrio; Frederico Guanais; Oye Gureje; Lisa R Hirschhorn; Lixin Jiang; Edward Kelley; Ephrem Tekle Lemango; Jerker Liljestrand; Address Malata; Tanya Marchant; Malebona Precious Matsoso; John G Meara; Manoj Mohanan; Youssoupha Ndiaye; Ole F Norheim; K Srinath Reddy; Alexander K Rowe; Joshua A Salomon; Gagan Thapa; Nana A Y Twum-Danso; Muhammad Pate Journal: Lancet Glob Health Date: 2018-09-05 Impact factor: 26.763
Authors: Bruno Vieira; Erwin W Hans; Corine van Vliet-Vroegindeweij; Jeroen van de Kamer; Wim van Harten Journal: BMC Med Inform Decis Mak Date: 2016-11-25 Impact factor: 2.796